CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 22, 2017--
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that the Company will
participate in the Leerink Partners Rare Disease Roundtable on
Wednesday, September 27, 2017, with a presentation at 2:00 p.m. ET in
New York, NY.
A live webcast of the presentation can be accessed on the investor page
of Sage's website at investor.sagerx.com.
A replay of the webcast will also be archived for up to 30 days on
Sage's website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders. Sage
has a portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage's lead program, brexanolone
(SAGE-547), is in Phase 3 clinical development for postpartum
depression. Sage is developing its next generation modulators, including
SAGE-217 and SAGE-718, in various CNS disorders. For more information,
please visit www.sagerx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170922005631/en/
Source: Sage Therapeutics
Investor Contact:
Sage Therapeutics
Paul Cox,
617-299-8377
paul.cox@sagerx.com
or
Media
Contact:
Suda Communications LLC
Maureen L. Suda,
585-387-9248
maureen.suda@sagerx.com
